Myriad Genetics, Inc. (NASDAQ:MYGN)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as $25.85 and last traded at $26.15, with a volume of 4786 shares trading hands. The stock had previously closed at $26.41.

Several equities analysts have recently commented on MYGN shares. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a research note on Thursday, January 17th. BidaskClub upgraded Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 20th. Finally, Needham & Company LLC restated a “strong-buy” rating and set a $41.00 price target (up previously from $37.00) on shares of Myriad Genetics in a research note on Tuesday, March 12th. Four analysts have rated the stock with a sell rating, three have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $39.19.

The company has a debt-to-equity ratio of 0.24, a current ratio of 3.15 and a quick ratio of 2.86. The company has a market cap of $1.93 billion, a PE ratio of 21.75, a PEG ratio of 1.59 and a beta of 0.55.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, May 7th. The company reported $0.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.04). Myriad Genetics had a net margin of 2.62% and a return on equity of 9.82%. The company had revenue of $216.60 million during the quarter, compared to analysts’ expectations of $217.76 million. During the same quarter last year, the firm earned $0.34 EPS. Myriad Genetics’s revenue for the quarter was up 18.3% on a year-over-year basis. On average, analysts expect that Myriad Genetics, Inc. will post 1.44 earnings per share for the current fiscal year.

In other Myriad Genetics news, insider Ralph L. Mcdade sold 1,975 shares of Myriad Genetics stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $31.00, for a total value of $61,225.00. Following the transaction, the insider now owns 122,604 shares in the company, valued at $3,800,724. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.80% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Oregon Public Employees Retirement Fund acquired a new stake in Myriad Genetics in the fourth quarter worth about $28,000. Pearl River Capital LLC boosted its holdings in Myriad Genetics by 154.9% in the first quarter. Pearl River Capital LLC now owns 882 shares of the company’s stock worth $30,000 after acquiring an additional 536 shares in the last quarter. Financial Gravity Companies Inc. acquired a new stake in Myriad Genetics in the fourth quarter worth about $42,000. Investors Research Corp acquired a new stake in Myriad Genetics in the first quarter worth about $46,000. Finally, Financial Gravity Wealth Inc. acquired a new stake in Myriad Genetics in the first quarter worth about $56,000. Institutional investors own 99.22% of the company’s stock.

WARNING: “Myriad Genetics (MYGN) Reaches New 52-Week Low at $25.85” was first posted by Marea Informative and is the property of of Marea Informative. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Article: How mutual funds make money

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with's FREE daily email newsletter.